Share Price and Basic Stock Data
Last Updated: January 22, 2026, 10:56 pm
| PEG Ratio | -8.82 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aster DM Healthcare Ltd operates in the Hospitals & Medical Services industry, with a current share price of ₹560 and a market capitalization of ₹28,989 Cr. The company’s revenue has shown significant fluctuations over the past few quarters. For instance, sales reported for September 2022 stood at ₹2,816 Cr, which increased to ₹3,192 Cr by December 2022. However, sales saw a sharp decline to ₹807 Cr in March 2023 before gradually recovering to ₹929 Cr by September 2023. Despite this volatility, the trailing twelve months (TTM) revenue is reported at ₹4,325 Cr, indicating a recovery trend. The revenue from operations per share for March 2025 is ₹82.85, up from ₹74.05 in March 2024, signifying a positive trajectory in operational efficiency. Overall, while the revenue trends display some instability, the recovery seen in recent quarters suggests potential for growth as the company stabilizes its operational framework.
Profitability and Efficiency Metrics
Aster DM Healthcare’s profitability has reflected both challenges and opportunities. The net profit for the financial year ending March 2025 recorded at ₹5,408 Cr shows a significant turnaround from a net profit of ₹475 Cr in March 2023. The operating profit margin (OPM) improved to 18% in March 2025, compared to 15% in March 2023, indicating better cost management and operational efficiency. However, the P/E ratio stands at 79.0, which is relatively high compared to typical sector ranges, suggesting that the stock may be overvalued at current earnings levels. The return on equity (ROE) stood at 156.87% for March 2025, significantly higher than many peers, demonstrating effective utilization of equity capital. Yet, the company faces risks related to fluctuating operating profits, as seen in quarterly reports where the OPM ranged from 11% to 20% over the past year, indicating inconsistent profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Aster DM Healthcare reveals a mixed picture of financial health. As of March 2025, total borrowings stood at ₹2,089 Cr against reserves of ₹4,015 Cr, suggesting a solid equity base to support debt levels. The interest coverage ratio (ICR) at 7.37x indicates that the company comfortably meets its interest obligations, reflecting prudent financial management. However, the debt-to-equity ratio of 0.18x is relatively low, suggesting minimal leverage compared to industry norms, which can be a double-edged sword, as it limits growth through leveraged investments. The book value per share, which has declined from ₹100.70 in March 2024 to ₹68.63 in March 2025, highlights concerns over capital retention. These financial ratios indicate that while Aster DM Healthcare maintains a robust balance sheet, the decline in book value and reliance on equity financing could pose challenges for future growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aster DM Healthcare indicates a diverse ownership structure, with promoters holding 40.39% as of September 2025. Foreign institutional investors (FIIs) have decreased their stake to 18.72%, down from 42.49% in December 2022, reflecting reduced confidence among international investors. Domestic institutional investors (DIIs) have increased their stake to 26.32%, suggesting growing confidence from local investment entities. The public shareholding stands at 14.33%, with a total of 1,47,304 shareholders, indicating a broad base of retail investors. The recent fluctuations in promoter and FII holdings may raise concerns regarding investor sentiment, especially given the decline in FII interest. However, the consistent DII investment and stability in public ownership could mitigate some risks associated with the changing dynamics of investor confidence.
Outlook, Risks, and Final Insight
Aster DM Healthcare faces a mixed outlook, buoyed by recent improvements in profitability and operational efficiency. However, risks persist, particularly in the form of fluctuating revenue and high P/E ratios, which could deter potential investors. The company’s ability to convert its recent operational improvements into sustainable growth will be critical. A potential upside scenario could involve continued revenue growth alongside further improvements in operating margins, potentially attracting renewed interest from FIIs. Conversely, persistent volatility in earnings or a downturn in market conditions could exacerbate investor concerns, leading to a potential decline in share price. The company’s focus on enhancing operational efficiencies and managing debt levels will be pivotal in navigating its growth trajectory in the competitive healthcare sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.8 Cr. | 137 | 187/120 | 9.34 | 117 | 2.56 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.9 Cr. | 20.9 | 33.0/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.4 | 20.5/7.08 | 120 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 104 Cr. | 55.7 | 98.7/52.2 | 23.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.8 Cr. | 3.48 | 6.94/3.37 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,866.00 Cr | 662.81 | 87.45 | 93.18 | 0.35% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,816 | 3,192 | 807 | 841 | 929 | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 |
| Expenses | 2,498 | 2,743 | 687 | 722 | 787 | 805 | 817 | 841 | 869 | 864 | 818 | 876 | 961 |
| Operating Profit | 319 | 449 | 120 | 119 | 142 | 149 | 156 | 161 | 217 | 186 | 182 | 202 | 236 |
| OPM % | 11% | 14% | 15% | 14% | 15% | 16% | 16% | 16% | 20% | 18% | 18% | 19% | 20% |
| Other Income | 18 | 10 | 149 | -17 | -64 | 153 | -40 | 5,120 | 35 | 9 | 5 | 29 | 28 |
| Interest | 77 | 87 | 25 | 25 | 30 | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 |
| Depreciation | 189 | 198 | 54 | 51 | 54 | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 |
| Profit before tax | 71 | 173 | 190 | 26 | -7 | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 | 167 |
| Tax % | 23% | 8% | 4% | 24% | 120% | 5% | 108% | 1% | 33% | 37% | 6% | 31% | 27% |
| Net Profit | 54 | 159 | 183 | 20 | -15 | 209 | -2 | 5,152 | 106 | 64 | 86 | 94 | 121 |
| EPS in Rs | 0.93 | 2.79 | 3.42 | 0.10 | -0.62 | 3.59 | -0.48 | 103.00 | 1.94 | 1.14 | 1.58 | 1.65 | 2.12 |
Last Updated: January 13, 2026, 1:21 am
Below is a detailed analysis of the quarterly data for Aster DM Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,197.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,078.00 Cr. (Jun 2025) to 1,197.00 Cr., marking an increase of 119.00 Cr..
- For Expenses, as of Sep 2025, the value is 961.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 876.00 Cr. (Jun 2025) to 961.00 Cr., marking an increase of 85.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 236.00 Cr.. The value appears strong and on an upward trend. It has increased from 202.00 Cr. (Jun 2025) to 236.00 Cr., marking an increase of 34.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Jun 2025) to 20.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Jun 2025) to 28.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 31.00 Cr..
- For Depreciation, as of Sep 2025, the value is 66.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 63.00 Cr. (Jun 2025) to 66.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 167.00 Cr.. The value appears strong and on an upward trend. It has increased from 136.00 Cr. (Jun 2025) to 167.00 Cr., marking an increase of 31.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be improving (decreasing) as expected. It has decreased from 31.00% (Jun 2025) to 27.00%, marking a decrease of 4.00%.
- For Net Profit, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Jun 2025) to 121.00 Cr., marking an increase of 27.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.12. The value appears strong and on an upward trend. It has increased from 1.65 (Jun 2025) to 2.12, marking an increase of 0.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,871 | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 2,994 | 3,699 | 4,138 | 4,325 |
| Expenses | 2,421 | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 2,547 | 3,124 | 3,384 | 3,520 |
| Operating Profit | 451 | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 447 | 575 | 754 | 805 |
| OPM % | 16% | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 15% | 16% | 18% | 19% |
| Other Income | 19 | 23 | 25 | 453 | 177 | -155 | -158 | 53 | 51 | 353 | 32 | 5,169 | 71 |
| Interest | 48 | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 96 | 119 | 133 | 125 |
| Depreciation | 111 | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 192 | 220 | 249 | 256 |
| Profit before tax | 310 | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 511 | 268 | 5,542 | 496 |
| Tax % | 9% | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 7% | 21% | 2% | |
| Net Profit | 284 | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 212 | 5,408 | 365 |
| EPS in Rs | 4.69 | 7.00 | 0.20 | 2.52 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 2.59 | 107.66 | 6.49 |
| Dividend Payout % | 35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 4,637% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -4.23% | -97.06% | 1125.00% | 187.76% | 30.14% | -14.17% | -43.49% | 237.64% | -20.97% | -55.37% | 2450.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | -92.83% | 1222.06% | -937.24% | -157.61% | -44.31% | -29.32% | 281.13% | -258.61% | -34.40% | 2506.31% |
Aster DM Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -14% |
| 3 Years: | -26% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -7% |
| 3 Years: | -17% |
| TTM: | 82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 38% |
| 3 Years: | 38% |
| 1 Year: | 56% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 | 518 |
| Reserves | 536 | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 3,686 | 2,554 | 4,015 |
| Borrowings | 886 | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 5,282 | 6,075 | 1,758 | 2,392 | 2,089 |
| Other Liabilities | 1,097 | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 3,661 | 4,687 | 12,039 | 1,154 | 1,186 |
| Total Liabilities | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
| Fixed Assets | 1,087 | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 3,175 | 3,920 | 4,024 |
| CWIP | 357 | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 170 | 293 | 401 |
| Investments | 7 | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 17 | 245 | 1,184 |
| Other Assets | 1,442 | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 14,620 | 2,142 | 2,199 |
| Total Assets | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
Below is a detailed analysis of the balance sheet data for Aster DM Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 500.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,015.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,554.00 Cr. (Mar 2025) to 4,015.00 Cr., marking an increase of 1,461.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,089.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,392.00 Cr. (Mar 2025) to 2,089.00 Cr., marking a decrease of 303.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,186.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,154.00 Cr. (Mar 2025) to 1,186.00 Cr., marking an increase of 32.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,808.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,024.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,920.00 Cr. (Mar 2025) to 4,024.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Sep 2025, the value is 401.00 Cr.. The value appears strong and on an upward trend. It has increased from 293.00 Cr. (Mar 2025) to 401.00 Cr., marking an increase of 108.00 Cr..
- For Investments, as of Sep 2025, the value is 1,184.00 Cr.. The value appears strong and on an upward trend. It has increased from 245.00 Cr. (Mar 2025) to 1,184.00 Cr., marking an increase of 939.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,199.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,142.00 Cr. (Mar 2025) to 2,199.00 Cr., marking an increase of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,808.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
Notably, the Reserves (4,015.00 Cr.) exceed the Borrowings (2,089.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -435.00 | 505.00 | 442.00 | 347.00 | 630.00 | -1.00 | -4.00 | -3.00 | -4.00 | 441.00 | 574.00 | 752.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 285 | 23 | 23 |
| Inventory Days | 71 | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 612 | 44 | 36 |
| Days Payable | 176 | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 1,400 | 183 | 166 |
| Cash Conversion Cycle | -18 | -2 | -1 | 30 | 45 | 50 | -65 | -83 | -66 | -503 | -116 | -107 |
| Working Capital Days | 61 | 69 | 68 | 6 | 59 | 28 | 8 | 5 | 5 | -21 | 272 | -32 |
| ROCE % | 18% | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 3% | 4% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 23,927,134 | 4.19 | 1592.23 | N/A | N/A | N/A |
| Kotak Small Cap Fund | 11,757,234 | 4.49 | 782.39 | N/A | N/A | N/A |
| Quant Small Cap Fund | 11,305,160 | 2.49 | 752.3 | 1,758,485 | 2025-12-08 07:20:44 | 542.89% |
| Nippon India Small Cap Fund | 9,522,707 | 0.92 | 633.69 | N/A | N/A | N/A |
| SBI Contra Fund | 9,199,605 | 1.23 | 612.19 | N/A | N/A | N/A |
| Kotak Midcap Fund | 6,137,365 | 0.68 | 408.41 | 5,738,292 | 2025-12-15 01:26:06 | 6.95% |
| Franklin India Small Cap Fund | 4,675,704 | 2.3 | 311.14 | 5,618,134 | 2025-12-15 01:26:06 | -16.77% |
| HDFC Childrens Fund | 3,759,174 | 2.35 | 250.15 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 3,574,000 | 1.47 | 237.83 | N/A | N/A | N/A |
| Franklin India Mid Cap Fund | 2,407,002 | 1.24 | 160.17 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 107.98 | 2.60 | 8.54 | 10.58 | 2.97 |
| Diluted EPS (Rs.) | 107.85 | 2.60 | 8.53 | 10.57 | 2.97 |
| Cash EPS (Rs.) | 113.62 | 8.87 | 25.12 | 24.96 | 15.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Revenue From Operations / Share (Rs.) | 82.85 | 74.05 | 238.89 | 206.21 | 173.19 |
| PBDIT / Share (Rs.) | 18.27 | 12.07 | 32.90 | 30.85 | 22.39 |
| PBIT / Share (Rs.) | 13.29 | 7.66 | 17.28 | 17.97 | 9.96 |
| PBT / Share (Rs.) | 9.81 | 5.46 | 10.69 | 12.80 | 4.05 |
| Net Profit / Share (Rs.) | 108.64 | 4.46 | 9.49 | 12.08 | 3.51 |
| NP After MI And SOA / Share (Rs.) | 107.66 | 2.59 | 8.51 | 10.58 | 2.97 |
| PBDIT Margin (%) | 22.05 | 16.29 | 13.77 | 14.96 | 12.92 |
| PBIT Margin (%) | 16.04 | 10.34 | 7.23 | 8.71 | 5.75 |
| PBT Margin (%) | 11.83 | 7.36 | 4.47 | 6.20 | 2.34 |
| Net Profit Margin (%) | 131.13 | 6.02 | 3.97 | 5.85 | 2.02 |
| NP After MI And SOA Margin (%) | 129.94 | 3.49 | 3.56 | 5.12 | 1.71 |
| Return on Networth / Equity (%) | 156.87 | 2.83 | 10.43 | 13.30 | 4.38 |
| Return on Capital Employeed (%) | 11.59 | 5.71 | 8.44 | 9.93 | 5.86 |
| Return On Assets (%) | 81.40 | 0.71 | 2.85 | 4.19 | 1.26 |
| Long Term Debt / Equity (X) | 0.14 | 0.09 | 0.32 | 0.37 | 0.52 |
| Total Debt / Equity (X) | 0.18 | 0.14 | 0.56 | 0.55 | 0.56 |
| Asset Turnover Ratio (%) | 0.33 | 0.22 | 0.18 | 0.14 | 0.09 |
| Current Ratio (X) | 2.16 | 1.25 | 1.06 | 1.15 | 1.14 |
| Quick Ratio (X) | 2.06 | 1.25 | 0.77 | 0.86 | 0.86 |
| Inventory Turnover Ratio (X) | 40.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 114.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 109.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | -9.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 7.37 | 5.46 | 4.99 | 5.97 | 3.79 |
| Interest Coverage Ratio (Post Tax) (X) | 4.28 | 2.96 | 2.44 | 3.34 | 1.59 |
| Enterprise Value (Cr.) | 23702.29 | 21464.85 | 14334.72 | 12129.54 | 8918.86 |
| EV / Net Operating Revenue (X) | 5.73 | 5.80 | 1.20 | 1.18 | 1.04 |
| EV / EBITDA (X) | 25.97 | 35.61 | 8.72 | 7.91 | 8.02 |
| MarketCap / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| Retention Ratios (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 7.06 | 4.48 | 2.96 | 2.48 | 2.02 |
| Price / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| EarningsYield | 0.22 | 0.01 | 0.03 | 0.05 | 0.02 |
After reviewing the key financial ratios for Aster DM Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 107.98. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.98, marking an increase of 105.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 107.85. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.85, marking an increase of 105.25.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.62. This value is within the healthy range. It has increased from 8.87 (Mar 24) to 113.62, marking an increase of 104.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.85. It has increased from 74.05 (Mar 24) to 82.85, marking an increase of 8.80.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 18.27. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 18.27, marking an increase of 6.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.29. This value is within the healthy range. It has increased from 7.66 (Mar 24) to 13.29, marking an increase of 5.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 9.81, marking an increase of 4.35.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 108.64. This value is within the healthy range. It has increased from 4.46 (Mar 24) to 108.64, marking an increase of 104.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 107.66. This value is within the healthy range. It has increased from 2.59 (Mar 24) to 107.66, marking an increase of 105.07.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 16.29 (Mar 24) to 22.05, marking an increase of 5.76.
- For PBIT Margin (%), as of Mar 25, the value is 16.04. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 16.04, marking an increase of 5.70.
- For PBT Margin (%), as of Mar 25, the value is 11.83. This value is within the healthy range. It has increased from 7.36 (Mar 24) to 11.83, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 131.13. This value exceeds the healthy maximum of 10. It has increased from 6.02 (Mar 24) to 131.13, marking an increase of 125.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 129.94. This value exceeds the healthy maximum of 20. It has increased from 3.49 (Mar 24) to 129.94, marking an increase of 126.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 156.87. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 156.87, marking an increase of 154.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.59. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 11.59, marking an increase of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 81.40. This value is within the healthy range. It has increased from 0.71 (Mar 24) to 81.40, marking an increase of 80.69.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has increased from 0.09 (Mar 24) to 0.14, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has increased from 0.14 (Mar 24) to 0.18, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has increased from 0.22 (Mar 24) to 0.33, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 2.16. This value is within the healthy range. It has increased from 1.25 (Mar 24) to 2.16, marking an increase of 0.91.
- For Quick Ratio (X), as of Mar 25, the value is 2.06. This value exceeds the healthy maximum of 2. It has increased from 1.25 (Mar 24) to 2.06, marking an increase of 0.81.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 40.80. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 40.80, marking an increase of 40.80.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 114.80. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 114.80, marking an increase of 114.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 109.73. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 109.73, marking an increase of 109.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is -9.73. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -9.73, marking a decrease of 9.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 7.37, marking an increase of 1.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.28. This value is within the healthy range. It has increased from 2.96 (Mar 24) to 4.28, marking an increase of 1.32.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23,702.29. It has increased from 21,464.85 (Mar 24) to 23,702.29, marking an increase of 2,237.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 5.73, marking a decrease of 0.07.
- For EV / EBITDA (X), as of Mar 25, the value is 25.97. This value exceeds the healthy maximum of 15. It has decreased from 35.61 (Mar 24) to 25.97, marking a decrease of 9.64.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For Retention Ratios (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 30. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Price / BV (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 4.48 (Mar 24) to 7.06, marking an increase of 2.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For EarningsYield, as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.22, marking an increase of 0.21.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aster DM Healthcare Ltd:
- Net Profit Margin: 131.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.59% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 156.87% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.28
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 81.4 (Industry average Stock P/E: 87.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 131.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Bengaluru Kerala 560027 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Azad Moopen | Founder Chairman & Mng. Director |
| Ms. Alisha Moopen | Deputy Managing Director |
| Mr. Daniel Robert Mintz | Non Executive Director |
| Mr. T J Wilson | Non Executive Director |
| Mr. Shamsudheen Bin Mohideen Mammu Haji | Non Executive Director |
| Dr. Zeba Azad Moopen | Non Executive Director |
| Mr. Anoop Moopen | Non Executive Director |
| Ms. Purana Housdurgamvijaya Deepti | Independent Director |
| Mr. Chenayappillil John George | Independent Director |
| Mr. Maniedath Madhavan Nambiar | Independent Director |
| Mr. Sunil Theckath Vasudevan | Independent Director |
| Dr. James Mathew | Independent Director |
| Mr. Emmanuel David Gootam | Independent Director |
FAQ
What is the intrinsic value of Aster DM Healthcare Ltd?
Aster DM Healthcare Ltd's intrinsic value (as of 23 January 2026) is ₹430.95 which is 25.18% lower the current market price of ₹576.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹29,886 Cr. market cap, FY2025-2026 high/low of ₹732/386, reserves of ₹4,015 Cr, and liabilities of ₹7,808 Cr.
What is the Market Cap of Aster DM Healthcare Ltd?
The Market Cap of Aster DM Healthcare Ltd is 29,886 Cr..
What is the current Stock Price of Aster DM Healthcare Ltd as on 23 January 2026?
The current stock price of Aster DM Healthcare Ltd as on 23 January 2026 is ₹576.
What is the High / Low of Aster DM Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aster DM Healthcare Ltd stocks is ₹732/386.
What is the Stock P/E of Aster DM Healthcare Ltd?
The Stock P/E of Aster DM Healthcare Ltd is 81.4.
What is the Book Value of Aster DM Healthcare Ltd?
The Book Value of Aster DM Healthcare Ltd is 87.5.
What is the Dividend Yield of Aster DM Healthcare Ltd?
The Dividend Yield of Aster DM Healthcare Ltd is 0.87 %.
What is the ROCE of Aster DM Healthcare Ltd?
The ROCE of Aster DM Healthcare Ltd is 10.7 %.
What is the ROE of Aster DM Healthcare Ltd?
The ROE of Aster DM Healthcare Ltd is 8.26 %.
What is the Face Value of Aster DM Healthcare Ltd?
The Face Value of Aster DM Healthcare Ltd is 10.0.